AKOYA_logo_white_smallAKOYA_logo_white_smallAKOYA_logo_white_smallAKOYA_logo_white_small
  • Search
  • Login Store
  • Contact Us
  • Technology
    • Why Spatial Biology
    • Intro to CODEX
    • Intro to Phenoptics
  • Applications
    • Clinical Applications
    • Discovery Applications
  • Products
    • Spatial Biology Solutions
    • CODEX® – Ultrahigh Multiplexed Imaging
    • PhenopticsTM – High-throughput Multiplexed Imaging
    • ProximaTM – Cloud Storage & Collaboration
    • Biopharma Services
  • Support
    • Hardware
    • Software
    • Reagents
    • FAQs
  • Resources
    • Akoya Academy
    • Literature
    • Videos
    • Webinars
    • Publications
    • Blog
  • Company
    • About Us
    • Leadership
    • Partners
    • Careers
    • News
    • Investors
    • Media Kit
    • Events
  • Technology
    • Why Spatial Biology
    • Intro to CODEX
    • Intro to Phenoptics
  • Applications
    • Clinical Applications
    • Discovery Applications
  • Products
    • Spatial Biology Solutions
    • Codex
    • Phenoptics
    • Proxima
    • Biopharma Services
  • Support
    • Hardware
    • Software
    • Reagents
    • FAQs
  • Resources
    • Akoya Academy
    • Literature
    • Videos
    • Webinars
    • Publications
    • Blog
  • Company
    • About Us
    • Leadership
    • Partners
    • News
    • Investors
    • Media Kit
    • Events
    • Careers
  • Home
  • Rova-T Enhances the Anti-Tumor Activity of Anti-PD1 in a Murine Model of Small Cell Lung Cancer with Endogenous Dll3 Expression

Rova-T Enhances the Anti-Tumor Activity of Anti-PD1 in a Murine Model of Small Cell Lung Cancer with Endogenous Dll3 Expression

Vitorino, P., Chuang, C. H., Iannello, A., Zhao, X., Anderson, W., Ferrando, R., ... & Saunders, L. R. (2021). Rova-T enhances the anti-tumor activity of anti-PD1 in a murine model of small cell lung cancer with endogenous Dll3 expression. Translational oncology, 14(1), 100883.

Authors: Philip Vitorino 1, Chen-Hua Chuang 2, Alexandre Iannello 3, Xi Zhao 4, Wade Anderson 5, Ronald Ferrando 4, Zhaomei Zhang 4, Shravanthi Madhavan 6, Holger Karsunky 7, Laura R Saunders 8

Online: https://www.sciencedirect.com/science/article/pii/S1936523320303752

Issue: Transl Oncol. 2021 Jan;14(1):100883.

Abstract

Rovalpituzumab tesirine (Rova-T) offers a targeted therapy for ~85% of SCLC patients whose tumors express DLL3, but clinical dosing is limited due to off-target toxicities. We hypothesized that a sub-efficacious dose of Rova-T combined with anti-PD1, which alone shows a clinical benefit to ~15% of SCLC patients, might elicit a novel mechanism of action and extend clinical utility. Using a pre-clinical murine SCLC tumor model that expresses Dll3 and has an intact murine immune system, we found that sub-efficacious doses of Rova-T with anti-PD1 resulted in enhanced anti-tumor activity, compared to either monotherapy. Multiplex immunohistochemistry (IHC) showed CD4 and CD8 T-cells primarily in normal tissue immediately adjacent to the tumor. Combination treatment, but not anti-PD1 alone, increased Ki67+/CD8 T-cells and Granzyme B+/CD8 in tumors by flow cytometry and IHC. Antibody depletion of T-cell populations showed CD8+ T-cells are required for in vivo anti-tumor efficacy. Whole transcriptome analysis as well as flow cytometry and IHC showed that Rova-T activates dendritic cells and increases Ccl5, Il-12, and Icam more than anti-PD1 alone. Increased tumor expression of PDL1 and MHC1 following Rova-T treatment also supports combination with anti-PD1. Mice previously treated with Rova-T + anti-PD1 withstood tumor re-challenge, demonstrating sustained anti-tumor immunity. Collectively our pre-clinical data support clinical combination of sub-efficacious Rova-T with anti-PD1 to extend the benefit of immune checkpoint inhibitors to more SCLC patients.

 

Follow Us



Technology

  • Why Spatial Biology
  • Intro to CODEX
  • Intro to Phenoptics

Applications

  • Clinical Applications
  • Discovery Applications

Products

  • Spatial Biology Solutions
  • CODEX
  • Phenoptics
  • Proxima
  • Biopharma Services

Resources

  • Akoya Academy
  • Literature
  • Videos
  • Webinars
  • Publications
  • Blog

Company

  • About Us
  • Leadership
  • Partners
  • News
  • Investors
  • Media Kit
  • Events
  • Careers



Akoya Biosciences and The Spatial Biology Company are registered trademarks of Akoya Biosciences, Inc. A Delaware corporation.
Copyright © All Rights Reserved. For Research Use Only. Not for use in diagnostic procedures.
Terms and Conditions Privacy Policy
    • Search
    • Login Store
    • Contact Us